AOI Biosciences Inc. (Headquarters: Ibaraki, Osaka; CEO: Shinichi Sueta; hereinafter referred to as “AOI Bio.”) today announced that its “β2GPI Neoself Antibody Test” has been approved as a new advanced medical technology for recurrent pregnancy loss. The University of Tokyo Hospital petitioned for the inclusion of the test into the advanced medical care program. This recognition allows the test to be used in combination with insurance-covered medical treatments. AOI Bio. will provide testing services, as the sole testing service provider for the Neoself Antibody Test.
About the β2GPI Neoself Antibody Test
This innovative blood test identifies neoself antibodies, which are implicated for miscarriages and thrombosis, accounting for approximately 20% of recurrent pregnancy loss cases. Recent studies have also reported a connection between these antibodies and infertility. Clinical research has demonstrated that, for patients with positive test results, implementing appropriate medical intervention led to a live birth rate approximately 1.7 times higher in recurrent pregnancy loss cases and a pregnancy rate more than twice as high in infertility cases. AOI Bio. holds exclusive rights to conduct this test, granted by Osaka University, and currently offers it to over 200 medical institutions across Japan.
About the Advanced Medical Care Program
Advanced medical care refers to treatments and technologies not yet covered by Japan’s national health insurance, but still recognized by the Ministry of Health, Labour and Welfare (MHLW). These treatments can be provided to patients simultaneously with insurance-covered medical services, under specific standards for participating medical facilities and methods established by the government. For the current list of advanced medical technologies, please refer to the following link (Japanese only): https://www.mhlw.go.jp/topics/bukyoku/isei/sensiniryo/kikan03.html
About AOI Biosciences Inc.
AOI Biosciences integrates bioinformatics with proprietary biotechnology, focusing on infectious diseases and autoimmune disorders. The company engages in diagnostic testing, drug discovery, and drug discovery support businesses, continuously contributing to the health and well-being of people worldwide.
- Company Overview
Company Name：AOI Biosciences株式会社（AOI Biosciences Inc.）
Current Address：Saito Bio Innovation Center, 7-7-20 Saito-Asagi, Ibaraki, Osaka, Japan
Representative：CEO Shinichi Sueta MD
Date of Incorporation：November 11, 2019
URL：https://www.aoibio.com/en/
URL (Neoself Test)：https://www.neoself.aoibio.com/english/
- For inquiries about this press release, contact
e-mail：hello@aoibio.com
